VEGFA and metastatic colorectal cancer: The recombinant humanized VEGF-A-specific monoclonal antibody, bevacizumab (Avastin; Genentech/Roche), was approved in 2004 by the US Food and Drug Administration for the first-line treatment of metastatic colorectal cancer [2].